Previous 10 | Next 10 |
Immunocore to present at Oppenheimer’s 32 nd Annual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering th...
Immunocore press release (NASDAQ:IMCR): FY GAAP EPS of -$4.19 misses by $0.18. Revenue of $35.8M (-12% Y/Y). For further details see: Immunocore GAAP EPS of -$4.19 misses by $0.18, revenue of $35.8M
PRESS RELEASE Immunocore Reports Full Year 202 1 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp- tebn ) approved by the FDA for the treatment of unresectable or metastatic uveal melanoma ; ...
Immunocore (NASDAQ:IMCR) said a committee of the European Medicines Agency (EMA) recommended the approval of its drug Kimmtrak (tebentafusp) to treat HLA-A 02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), a type of cancer affecting the eye. The re...
P RESS RELEASE Immunocore receives positive CHMP opinion for KIMMTRAK ® ( tebentafusp ) for the treatment of unresectable or metastatic uveal melanoma If approved by the European Medicines Agency, KIMMTRAK will b...
Immunocore to present at the SVB Leerink Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 February 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the developme...
Immunocore announces FDA approval of KIMMTRAK ® ( tebentafusp- tebn ) for the treatment of unresectable or metastatic uveal melanoma KIMMTRAK is the first and only FDA approved therapy for the treatment of unresect...
Immunocore to present at the 40 th Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 6 January 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the dev...
Immunocore a nnounces i nitial Phase 1 d ata of ImmTAC ® candidate I MC-C103C targeting MAGE-A4 Clinical activity with confirmed durable responses in ovarian cancer and a confirmed durable response in HNSCC M ...
P RESS RELEASE Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 November 2021) Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pi...
News, Short Squeeze, Breakout and More Instantly...
Immunocore Holdings plc Company Name:
IMCR Stock Symbol:
NASDAQ Market:
Immunocore Holdings plc Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...
A look at the top 10 most actives in the United States NLS Pharmaceutics Ltd. (NLSP) rose 156.2% to $0.38 on volume of 125,047,059 shares Reliance Global Group Inc. (RELI) rose 210.8% to $0.69 on volume of 110,427,102 shares Mustang Bio Inc. (MBIO) rose 53.3% to $1.15 on volume of 87,727,...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma The Phase 3 PRISM-MEL-301 trial will study the efficacy and safety of brenetafusp (IMC-F10...